The 1st International Workshop on HIV and Hepatitis Co-infection was held in Noordwijk, the Netherlands, 2–4 December 2004. This report outlines issues raised at the workshop concerning the treatment of hepatitis C in HIV-coinfected patients. Clinical trials using pegylated interferon in combination with ribavirin have provided positive outcomes, although clinicians still face a number of challenges in learning how best to use these drugs.
References
1.
RockstrohJ., KonopnickiD., SorianoV., KirkO., AntunesF., KnyszB., TuralC., De WitS., MocroftA., LundgrenJ. & EuroSIDA study group. Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART.11th Conference on Retroviruses & Opportunistic Infections. 8–11 February 2004, San Francisco, CA, USA. Abstract 799.
2.
SulkowskiM.S., & ThomasD.L.Hepatitis C in the HIV-infected person.Annals of Internal Medicine2003; 138: 197–207.
3.
BicaI., McGovernB., DharR., StoneD., McGowanK., ScheibR., & SnydmanD.R.Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.Clinical Infectious Diseases2001; 32: 492–497.
4.
Martin-CarboneroL., SorianoV., ValenciaE., Garcia-SamaniegoJ., LopezM., & Gonzalez-LahozJ.Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.AIDS Research & Human Retroviruses2001; 17: 1467–1471.
5.
BenhamouY., BochetM., Di MartinoV., CharlotteF., AzriaF., CoutellierA., VidaudM., BricaireF., OpolonP., KatlamaC., & PoynardT.Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.Hepatology1999; 30: 1054–1058.
6.
QurishiN., KreuzbergC., LuchtersG., EffenbergerW., KupferB., SauerbruchT., RockstrohJ.K., & SpenglerU.Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.Lancet2003; 362: 1708–1713.
7.
SpenglerU., LichterfeldM., & RockstrohJ.K.Antiretroviral drug toxicity – a challenge for the hepatologist?Journal of Hepatology2002; 36: 283–294.
8.
MannsM.P., McHutchisonJ.G., GordonS.C., RustgiV.K., ShiffmanM., ReindollarR., GoodmanZ.D., KouryK., LingM., & AlbrechtJ.K.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
9.
FriedM.W., ShiffmanM.L., ReddyK.R., SmithC., MarinosG., GoncalesF.L.Jr., HaussingerD., DiagoM., CarosiG., DhumeauxD., CraxiA., LinA., HoffmanJ., & YuJ.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.New England Journal of Medicine2002; 347: 975–982.
10.
TorrianiF.J., Rodriguez-TorresM., RockstrohJ.K., LissenE., Gonzalez-GarciaJ., LazzarinA., CarosiG., SasadeuszJ., KatlamaC., MontanerJ., SetteH., PasseS., De PamphilisJ., DuffF., SchrenkU.M., & DieterichD.T., for the APRICOT study group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.New England Journal of Medicine2004; 351: 438–450.
11.
ChungR.T., AndersenJ., VolberdingP., RobbinsG.K., LuiT., ShermanK.E., PetersM.G., KozielM.J., BhanA.K., AlstonB., ColquhounD., NevinT., HarbG., & van der HorstC., for the AIDS Clinical Trials Group A5071 study team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.New England Journal of Medicine2004; 351: 451–459.
12.
LagunoM., MurillasJ., BlancoJ.L., MartinezE., MiquelR., Sanchez-TapiasJ.M., BargalloX., Garcia-CriadoA., de LazzariE., LarrousseM., LeonA., LoncaM., MilinkovicA., GatellJ.M., & MallolasJ.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.AIDS2004; 18: F27–36.
13.
CarratF., Bani-SadrF., PolS., RosenthalE., Lunel-FabianiF., BenzekriA., MorandP., GoujardC., PialouxG., PirothL., Salmon-CeronD., DegottC., CacoubP., & PerronneC., for the ANRS HCO2 RIBAVIC study team. Pegylated inter-feron alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients.Journal of the American Medical Association2004; 292: 2839–2848.
14.
RamosB., NunezM., CaminoN., RomeroM., OcampoA., BarreiroP., MirallesC., Martin-CarboneroL., Garcia-SamaniegoJ., & SorianoV., on behalf of the PRESCO group. Early HCV-RNA clearance in HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin.1st International Workshop on HIV & Hepatitis Co-infection. 2–4 December 2004, Noordwijk, the Netherlands. Abstract CI14.
